A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2001
10/25/2001	US20010034440 Complexing the target cell with therapeutic agent; antiproliferative agent
10/25/2001	US20010034371 Antidiabetic agents
10/25/2001	US20010034370 Carnosic acid derivatives for promoting synthesis of nerve growth factor
10/25/2001	US20010034362 Pyrrolidine derivatives for vision and memory disorders
10/25/2001	US20010034361 Amide derivatives for antiangiogenic and/or antitumorigenic use
10/25/2001	US20010034359 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
10/25/2001	US20010034353 Administering a mixture of antibiotic, nonsteroid antiinflammatory drug and a quinolone compound
10/25/2001	US20010034352 Cardiovascular disorders
10/25/2001	US20010034351 A quinazoline compound
10/25/2001	US20010034348 Nitric oxide synthase inhibitor; nervous system disorders
10/25/2001	US20010034345 Administering a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
10/25/2001	US20010034337 Antiproliferative agents
10/25/2001	US20010034334 Genetic engineered polypeptide
10/25/2001	US20010034331 Isolated polypeptide
10/25/2001	US20010034329 Nucleic acids
10/25/2001	US20010034324 Immunostimulation
10/25/2001	US20010034051 For example: (2-(3-amino-4-nitrophenyl)amino)ethyl)(6-(2,4-dichlorophenyl-5-nitropyrazin -2-yl)-amine; antidiabetic, -carcingenic and ischemic agents; nervous and cardiovascular system disorders; immunotherapy; obesity; syndromes
10/25/2001	US20010033845 Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
10/25/2001	US20010033834 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
10/25/2001	US20010032643 Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage
10/25/2001	DE10020517A1 New 13-halo or cyano-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease
10/25/2001	DE10019062A1 Use of known and new 2-guanidino-4-aryl-quinazoline derivatives as NHE-3 inhibitors useful for the treatment of e.g. hypertension, thrombosis, cardiac ischemia, peripheral and CNS ischemia
10/25/2001	DE10018401A1 Medicament for treating hypertrophy-related myocardial disease, containing bradycardic agent, preferably cilobradine, and optionally another cardiac drug
10/25/2001	CA2747325A1 Albumin fusion proteins
10/25/2001	CA2575059A1 Pharmaceutical compositions comprising cilobradine
10/25/2001	CA2407531A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives
10/25/2001	CA2407031A1 Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
10/25/2001	CA2406481A1 Trp8, a transient receptor potential channel expressed in taste receptor cells
10/25/2001	CA2406475A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
10/25/2001	CA2406442A1 Hydrazide and alkoxyamide angiogenesis inhibitors
10/25/2001	CA2406383A1 A.beta.42 lowering agents
10/25/2001	CA2406245A1 Il-174 uses, compositions and methods
10/25/2001	CA2406226A1 Rapid-onset formulation of a selective cyclooxigenase-2
10/25/2001	CA2406220A1 Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease
10/25/2001	CA2406213A1 Compositions and methods for the therapy and diagnosis of breast cancer
10/25/2001	CA2406195A1 Lipid binding protein 4
10/25/2001	CA2406192A1 Therapeutic compounds and methods for formulating v3, a versican isoform
10/25/2001	CA2406032A1 Dihydro-2h-naphthalene-1-one inhibitors of ras farnesyl transferase
10/25/2001	CA2406023A1 Decreasing the intracellular level of beta-catenin by administering hydroxymatairesinol
10/25/2001	CA2405709A1 Albumin fusion proteins
10/25/2001	CA2405701A1 Albumin fusion proteins
10/25/2001	CA2405696A1 5-substituted tetralones as inhibitors of ras farnesyl transferase
10/25/2001	CA2405597A1 Halogentated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001	CA2405563A1 Albumin fusion proteins
10/25/2001	CA2405557A1 Albumin fusion proteins
10/25/2001	CA2405555A1 Pluripotent cells comprising allogenic nucleus and mitochondria
10/25/2001	CA2405550A1 Albumin fusion proteins
10/25/2001	CA2405525A1 Albumin fusion proteins
10/25/2001	CA2404858A1 Treatment of neurodegenerative disease
10/25/2001	CA2404117A1 Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
10/25/2001	CA2404097A1 Method and compositions for preventing hormone induced adverse effects
10/25/2001	CA2403591A1 Pharmaceutical compositions comprising fluvastatin
10/25/2001	CA2403490A1 N-substituted dithiocarbamates for the treatment of biological disorders
10/25/2001	CA2399940A1 Enhancement of antibody-mediated immune responses
10/25/2001	CA2398446A1 Pyrazoles for inhibiting protein kinases
10/25/2001	CA2370487A1 Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
10/24/2001	EP1148059A1 Thiazolopyrimidine compounds, process for the preparation of the same and uses thereof
10/24/2001	EP1148054A1 Thyroid receptor ligands
10/24/2001	EP1148049A1 Crystalline R-(R,R)$-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl -1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
10/24/2001	EP1147785A2 Therapeutic light source
10/24/2001	EP1147777A1 Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors
10/24/2001	EP1147776A2 Use of botulinum toxin type B for the manufacture of a medicament for the treatment of muscle spasms
10/24/2001	EP1147775A2 Use of botulinum toxin type B for the manufacture of a medicament for reducing pain associated with a muscle disorder
10/24/2001	EP1147773A1 Medicinal compositions for treating osseous lesion in multiple myeloma
10/24/2001	EP1147770A1 Virginiamycin mixture
10/24/2001	EP1147422A1 Assays for modulators of "elongation factor p" activity
10/24/2001	EP1147224A1 Method of diagnosing of exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes
10/24/2001	EP1147223A1 Identifying, monitoring, and treating women for breast precancer or cancer
10/24/2001	EP1147214A1 A novel method for designing protein kinase inhibitors
10/24/2001	EP1147209A2 Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
10/24/2001	EP1147193A1 Platelet-derived growth factor/vascular endothelial growth factor-like growth factor h, and uses thereof
10/24/2001	EP1147191A1 Transcriptional regulation of the human beta3-adrenergic receptor gene
10/24/2001	EP1147176A1 Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
10/24/2001	EP1147175A2 Fibres for culturing eukaryotic cells
10/24/2001	EP1147138A1 Hydrophilic ampholytic polymer
10/24/2001	EP1147133A2 Pth functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
10/24/2001	EP1147124A2 Steroid sulfatase inhibitors and methods for making and using the same
10/24/2001	EP1147114A1 Novel aralkyl amines of spirofuropyridines useful in therapy
10/24/2001	EP1147113A1 Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases
10/24/2001	EP1147110A1 Pyrazino(aza)indole derivatives
10/24/2001	EP1147107A1 Novel angiogenesis inhibitors
10/24/2001	EP1147103A1 Phenantrhridine-n-oxides with pde-iv inhibiting activity
10/24/2001	EP1147102A2 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
10/24/2001	EP1147101A1 Reverse hydroxamate inhibitors of matrix metalloproteinases
10/24/2001	EP1147095A1 2, 3, 4, 5-tetrahydro-1h-[1, 4] benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors
10/24/2001	EP1147094A1 Non-peptide glp-1 agonists
10/24/2001	EP1147093A1 Substituted bicyclic derivatives useful as anticancer agents
10/24/2001	EP1147092A1 Substituted imidazoles, their preparation and use
10/24/2001	EP1147088A1 6-arylphenanthridines with pde-iv inhibiting activity
10/24/2001	EP1147084A1 Phenylsulphonyl derivatives as 5-ht receptor ligands
10/24/2001	EP1147080A1 Alkynyl containing hydroxamic acid compounds as tace inhibitors
10/24/2001	EP1147079A2 Beta-phenylalanine derivatives as integrin antagonists
10/24/2001	EP1147078A1 Acetylenic (beta)-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors
10/24/2001	EP1146908A1 Formulations comprising antisense nucleotides to connexins
10/24/2001	EP1146907A2 Use of cationic lipids to generate anti-tumor immunity
10/24/2001	EP1146905A1 Cox-2 inhibitors in combination with nmda-blockers for treating pain
10/24/2001	EP1146901A1 Potentiation of anti-cd38-immunotoxin cytotoxicity
10/24/2001	EP1146899A1 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
10/24/2001	EP1146897A1 Use of a melanoma inhibiting activity factor (mia) for cartilage and bone repair
10/24/2001	EP1146894A1 Uses of thank, a tnf homologue that activates apoptosis

1 ... 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 ... 1564